Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency

23 de octubre de 2026 actualizado por: Immedica Pharma AB

A Phase 1/2 Open-label Study in Patients With Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102

A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102. This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase 1 deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing. A data safety monitoring board (DSMB) will provide independent review of study safety data and recommend whether the sponsor should continue the study as planned, modify the study protocol, or discontinue the study.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

16

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ontario
      • Toronto, Ontario, Canadá, M5G 1X8
        • The Hospital for Sick Children
    • California
      • Stanford, California, Estados Unidos, 94305
        • Stanford University School of Medicine
    • Florida
      • Gainesville, Florida, Estados Unidos, 32611
        • University of Florida
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Children's Hospital of Michigan
    • New York
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine at Mount Sinai
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • UTSW
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Seattle Children's Hospital
      • Porto, Portugal
        • Centro Hospitalar S. Joao
      • London, Reino Unido
        • Great Ormond Street Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or female ≥ 2 years
  • Documented diagnosis of Arginase 1 deficiency
  • Adequate organ function as defined by laboratory assessment
  • If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
  • If a sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
  • Patient or legal guardian is able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification) prior to any screening procedures

Exclusion Criteria:

  • Transfusion of ≥ 2 units of RBCs within 60 days
  • Active infection requiring systemic treatment
  • Known infection with HIV, Hep B or Hep C
  • Unstable hyperammonemia requiring hospitalization within 14 days
  • Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation
  • If female, is lactating or breast feeding

PART 2 INCLUSION CRITERION:

1. Did not experience any safety or tolerability event in Part 1 which would preclude continued participation and dosing of AEB1102

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: AEB1102

AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.

Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy.

modified human arginase I

Otros nombres:
  • Co-ArgI-PEG

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Adverse Events Related to ECGs
Periodo de tiempo: Weekly throughout the study, up to 14 weeks (Part 2 week 8)

The primary means of assessing ECG results was through assessing AEs related to ECGs.

Weekly throughout the study, up to 14 weeks (Part 2 week 8)
Number of Participants With Adverse Events Related to Clinical Laboratory Results
Periodo de tiempo: Weekly throughout the study, up to 14 weeks (Part 2 week 8)

The primary means of assessing clinical laboratory results was through assessing AEs related to clinical laboratory results. Laboratory studies included hematology, chemistry, urinalysis, and coagulatio.

Weekly throughout the study, up to 14 weeks (Part 2 week 8)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pharmacokinetic Profile of IV AEB1102: Time of the Maximum Observed Concentration (Tmax)
Periodo de tiempo: After 8 weeks of repeat-dosing (Part 2)

Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively.

After 8 weeks of repeat-dosing (Part 2)
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Through the Time of the Last Measurable Concentration (AUC0-t)
Periodo de tiempo: After 8 weeks of repeat-dosing (Part 2)

Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively.

After 8 weeks of repeat-dosing (Part 2)
Pharmacokinetic Profile of IV AEB1102: Maximum Observed Concentration (Cmax)
Periodo de tiempo: After 8 weeks of repeat-dosing (Part 2)

Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively.

After 8 weeks of repeat-dosing (Part 2)
Pharmacokinetic Profile of IV AEB1102: Apparent Terminal Elimination Half-life (T1/2)
Periodo de tiempo: After 8 weeks of repeat-dosing (Part 2)

Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively.

After 8 weeks of repeat-dosing (Part 2)
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Extrapolated to Infinity (AUC0-∞)
Periodo de tiempo: After 8 weeks of repeat-dosing (Part 2)

Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively.

After 8 weeks of repeat-dosing (Part 2)
Pharmacokinetic Profile of IV AEB1102: Serum Clearance (CL)
Periodo de tiempo: After 8 weeks of repeat-dosing (Part 2)

Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively.

After 8 weeks of repeat-dosing (Part 2)
Pharmacokinetic Profile of IV AEB1102: Volume of Distribution (Vss)
Periodo de tiempo: After 8 weeks of repeat-dosing (Part 2)

Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively.

After 8 weeks of repeat-dosing (Part 2)
Plasma Arginine Concentrations After AEB1102 IV
Periodo de tiempo: 168 hrs post dose, Part 2: Change from Baseline to 8 weeks

Plasma arginine concentration post dose AEB1102 IV

168 hrs post dose, Part 2: Change from Baseline to 8 weeks
Effect of AEB1102 on Plasma Guanidino Compounds: Guanidinoacetic Acid (GAA)
Periodo de tiempo: Part 2: Change from Baseline to 8 weeks

Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration

Part 2: Change from Baseline to 8 weeks
Effect of AEB1102 on Plasma Guanidino Compounds: α-keto-δ-guanidinovaleric Acid (GVA)
Periodo de tiempo: Part 2: Change from Baseline to 8 weeks

Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration

Part 2: Change from Baseline to 8 weeks
Effect of AEB1102 on Plasma Guanidino Compounds: Argininic Acid (ARGA)
Periodo de tiempo: Part 2: Change from Baseline to 8 weeks

Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration

Part 2: Change from Baseline to 8 weeks
Effect of AEB1102 on Plasma Guanidino Compounds: N-α-acetyl-L-arginine (NAA)
Periodo de tiempo: Part 2: Change from Baseline to 8 weeks

Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration

Part 2: Change from Baseline to 8 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Director de estudio: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de agosto de 2016

Finalización primaria (Actual)

28 de febrero de 2019

Finalización del estudio (Actual)

28 de febrero de 2019

Fechas de registro del estudio

Enviado por primera vez

29 de junio de 2015

Primero enviado que cumplió con los criterios de control de calidad

30 de junio de 2015

Publicado por primera vez (Estimado)

2 de julio de 2015

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir